Quick Answer
HOOKIPA Pharma Inc. reported Diluted EPS of $3.47 per share (loss) for fiscal year 2024.
HOOKIPA Pharma Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$3.47 | +59.8% |
| 2023 | -$8.63 | +12.9% |
| 2022 | -$9.91 | -330.9% |
| 2021 | -$2.30 | -36.1% |
| 2020 | -$1.69 | +29.9% |
| 2019 | -$2.41 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | -$1.23 | -207.9% | -11.8% |
| September 30, 2024 | -$1.10 | +36.4% | +27.6% |
| June 30, 2024 | -$1.52 | +30.3% | -233.3% |
| March 31, 2024 | $1.14 | +522.2% | +165.9% |
| September 30, 2023 | -$1.73 | -592.0% | +20.6% |
| June 30, 2023 | -$2.18 | -847.8% | -707.4% |
| March 31, 2023 | -$0.27 | +32.5% | -8.0% |
| September 30, 2022 | -$0.25 | +59.0% | -8.7% |
- HOOKIPA Pharma Inc. showed an increase of +59.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2024 period, HOOKIPA Pharma Inc.’s diluted eps has declined by 44.0% (from $2.41 per share (loss) to $3.47 per share (loss)).
- The most recent figure is from HOOKIPA Pharma Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: